Live
BioPharma DiveEli Lilly issues data sharing ultimatum to 340B hospitalsFierceBiotechASCO: Roche, head held high, details oral SERD's first-line flop in breast cancerBioPharma DiveFulcrum exploring a potential sale after FDA sidelined its sickle cell drugEndpoints NewsWhat’s next for VEGF? #ASCO26 offered clues, but answers will have to waitFierceBiotechTravere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseasesEndpoints NewsMale contraception startup closes $92.5M Series B; Novartis bets on actiniumEndpoints NewsTravere pays Everest $112M upfront to grow rare kidney disease pipelineEndpoints NewsLegend Biotech shares first in vivo CAR-T data, its next act after CarvyktiFierceBiotechFulcrum scraps SCD program, considers options after FDA takes hard line on safety risksFierceBiotechASCO: Cardiff posts updated colorectal cancer data ahead of pivotal pushPharmaVoiceAs amyloid falls out of favor, here’s where Alzheimer’s R&D is headed nextBioWorldJanssen Pharmaceutica reports new TMEM175 activators
FierceBiotech Apr 17, 2026

Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans

Merck unveils PD-1xVEGF bispecific data in NSCLC, remains tight-lipped on phase 3 plans

Original
Body unavailable. Use the original source.